SCHEMBL3611275

SCHEMBL3611275

O=C(Cc1csc(NS(=O)(=O)c2ccc(-c3cccs3)cc2)n1)N1CCOCC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.59
HSD17B1 P14061 1/20 0.51
HSD17B2 P37059 1/20 0.51
ALDH1A1 P00352 3/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
IRS1 P35568 1/20 0.44
POLB P06746 1/20 0.43
KMT2A Q03164 5/20 0.43
MEN1 O00255 4/20 0.43
PKM P14618 1/20 0.42
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
PHGDH O43175 1/20 0.40
TSHR P16473 1/20 0.40
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CCNA1 P78396 1/20 0.39
CDK5 Q00535 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3614418 0.89 HSD11B1 (0.63) HSD11B1HSD17B1HSD17B2ALDH1A1CYP2C9
SCHEMBL3252937 0.89 HSD11B1 (0.63) HSD11B1HSD17B1HSD17B2ALDH1A1CYP2C9
SCHEMBL3623030 0.87 HSD11B1 (0.56) HSD11B1HSD17B1HSD17B2ALDH1A1CYP2C9
SCHEMBL3615296 0.86 HSD11B1 (0.67) HSD11B1HSD17B1HSD17B2ALDH1A1CYP2C9
SCHEMBL3620339 0.86 HSD11B1 (0.58) HSD11B1HSD17B1HSD17B2ALDH1A1CYP2C9
SCHEMBL3620848 0.86 HSD11B1 (0.60) HSD11B1HSD17B1HSD17B2ALDH1A1CYP2C9
SCHEMBL3619549 0.86 HSD11B1 (0.70) HSD11B1HSD17B1HSD17B2POLBKMT2A
SCHEMBL3622062 0.86 HSD11B1 (0.62) HSD11B1HSD17B1HSD17B2ALDH1A1CYP2C9
SCHEMBL5830925 0.85 HSD11B1 (0.44) HSD11B1ALDH1A1IRS1POLBKMT2A
SCHEMBL3615845 0.85 HSD11B1 (0.61) HSD11B1HSD17B1HSD17B2ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 US claimed
US-7618961-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2009-11-17 US claimed
CN-1249039-C Inhibitors of 11 beta-hydroxysteroid dehydrogenase type I BIOVITRUM AB (SE) 2006-04-05 CN claimed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 US claimed
CN-1438997-A Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I BIOVITRUM AB (SE) 2003-08-27 CN claimed
US-8586588-B2 Aryl pyridazinone derivatives and their use as H3 receptor ligands CEPHALON, INC. (US) 2013-11-19 US disclosed
US-20100273779-A1 Pyridazinone Derivatives CEPHALON, INC. (US) 2010-10-28 US disclosed
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 US disclosed
US-7618961-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2009-11-17 US disclosed
CN-1249039-C Inhibitors of 11 beta-hydroxysteroid dehydrogenase type I BIOVITRUM AB (SE) 2006-04-05 CN disclosed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 US disclosed
CN-1438997-A Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I BIOVITRUM AB (SE) 2003-08-27 CN disclosed
EP-1283831-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 EP disclosed
WO-2001090090-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD3B1 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885
US-20100273779-A1 Pyridazinone Derivatives HRH3, HNMT, HRH4 HSD11B1 716/4885HSD17B1 356/4885HSD17B2 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.